Literature DB >> 25785003

Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis.

Wenjin Ding1, Jiangao Fan1, Jianjun Qin2.   

Abstract

BACKGROUND AND AIMS: Several existing studies indicated that nonalcoholic fatty liver disease (NAFLD) may be associated with colorectal adenoma, but the results and risk factors are controversial. A systematic review of studies was conducted to explore these issues by meta-analysis.
METHODS: We searched the Pubmed, Embase, Cochrane library, Medline and Web of Science databases for studies published before May 30(th), 2014. A statistical analysis was performed using RevMan 5.2 software.
RESULTS: Seven studies involving 11,905 participants from different regions were included. Among them, five trials carried out subgroup of NAFLD patients in colorectal adenoma population. The result showed NAFLD was significantly correlated with adenoma of colon (Odds ratio [OR] = 1.56, 95% confidence interval [CI]: 1.22-1.99, P = 0.0003). It could be found in stratified analysis that patients had more chance to get multiple adenomas when they suffered NAFLD (Rate ratio [RR]: 1.52, 95% CI: 1.08-2.13, P = 0.02). Such risk factors of NAFLD as age, waist circumference, body mass index (BMI), disorder of lipid metabolism, hyperglycemia and high blood pressure (HBP) increased risk of colorectal adenoma (Age: mean difference [MD]: 2.81, 95% CI: 0.33-5.28; Waist: MD: 2.84, 95% CI: 2.14-3.54; BMI: MD: 0.85, 95% CI: 0.69-1.01; High-density lipoprotein: MD: -2.46, 95% CI: -3.68 to -1.24; Triglyceride: MD: 16.12, 95% CI: 8.89-23.36; Low-density lipoprotein: MD: 6.04, 95% CI: 3.60-8.48; Cholesterol: MD: 4.25, 95% CI: 0.87-7.63; Fasting glucose: MD: 2.27, 95% CI: 1.24-3.30; HBP: OR = 1.51, 95% CI: 1.22-1.88), while diabetes had no significant association with it (OR = 1.43, 95% CI: 0.94-2.17, P = 0.09). Besides, NAFLD didn't affect the location, size and advanced type of colorectal adenoma (P > 0.05).
CONCLUSION: The present systematic review and meta-analysis demonstrated NAFLD was closely associated with great risk of colorectal adenoma and its number, but not with its location, size and advanced type. Waist, obesity, lipid profiles, glucose, hypertension played roles in the process of colorectal adenoma.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; colorectal adenoma; meta-analysis; risk factors

Year:  2015        PMID: 25785003      PMCID: PMC4358458     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  32 in total

Review 1.  Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target.

Authors:  Luca Miele; Giuseppe Marrone; Cristiano Lauritano; Consuelo Cefalo; Antonio Gasbarrini; Chris Day; Antonio Grieco
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

2.  Clinical association between non-alcoholic fatty liver disease and the development of hypertension.

Authors:  Jae-Hong Ryoo; Young Ju Suh; Ho Cheol Shin; Yong Kyun Cho; Joong-Myung Choi; Sung Keun Park
Journal:  J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 4.029

3.  Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study.

Authors:  Xian-Feng Lin; Ke-Qing Shi; Jie You; Wen-Yue Liu; Ying-Wan Luo; Fa-Ling Wu; Yong-Ping Chen; Danny Ka-Ho Wong; Man-Fung Yuen; Ming-Hua Zheng
Journal:  Mol Biol Rep       Date:  2014-01-22       Impact factor: 2.316

4.  Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer.

Authors:  Yang Won Min; Hwan Sic Yun; Woo Ik Chang; Jin Yong Kim; Young-Ho Kim; Hee Jung Son; Jae J Kim; Jong Chul Rhee; Dong Kyung Chang
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-11-30       Impact factor: 2.947

5.  Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia.

Authors:  A Stadlmayr; E Aigner; B Steger; L Scharinger; D Lederer; A Mayr; M Strasser; E Brunner; A Heuberger; F Hohla; J Steinwendner; W Patsch; C Datz
Journal:  J Intern Med       Date:  2011-04-25       Impact factor: 8.989

6.  Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease.

Authors:  Nadege T Touzin; Kelvin N V Bush; Christopher D Williams; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2011-05       Impact factor: 4.409

7.  Fasting serum insulin levels and insulin resistance are associated with colorectal adenoma in Koreans.

Authors:  Eun Hee Kim; Hong-Kyu Kim; Sung Jin Bae; Hye-Sook Chang; Hye Won Park; Mi Young Do; Kyung-Jo Kim; Chang Hee Jung; Woo Je Lee; Joong-Yeol Park; Jaewon Choe
Journal:  J Diabetes Investig       Date:  2013-12-05       Impact factor: 4.232

8.  Colorectal advanced neoplasms occur through dual carcinogenesis pathways in individuals with coexisting serrated polyps.

Authors:  Atsushi Yamada; Sachiko Minamiguchi; Yoshiharu Sakai; Takahiro Horimatsu; Manabu Muto; Tsutomu Chiba; C Richard Boland; Ajay Goel
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

Review 9.  Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.

Authors:  Elaine Hui; Aimin Xu; Hong Bo Yang; Karen S L Lam
Journal:  J Diabetes Investig       Date:  2013-05-06       Impact factor: 4.232

Review 10.  The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome.

Authors:  Said O Muhidin; Ahmed A Magan; Khalid A Osman; Shareef Syed; Mohamed H Ahmed
Journal:  J Obes       Date:  2012-12-10
View more
  14 in total

Review 1.  Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 2.  Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.

Authors:  Raseen Tariq; Page Axley; Ashwani K Singal
Journal:  J Clin Exp Hepatol       Date:  2019-07-25

Review 3.  Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia.

Authors:  Michael W Gleeson
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

4.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

5.  IκBζ regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice.

Authors:  Hideki Ishikawa; Morisada Hayakawa; Nemekhbayar Baatartsogt; Nao Kakizawa; Hiromi Ohto-Ozaki; Takashi Maruyama; Kouichi Miura; Koichi Suzuki; Toshiki Rikiyama; Tsukasa Ohmori
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

6.  Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy.

Authors:  Nam Hee Kim; Yoon Suk Jung; Jung Ho Park; Dong Il Park; Chong Il Sohn
Journal:  Korean J Intern Med       Date:  2020-07-07       Impact factor: 2.884

Review 7.  Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran.

Authors:  I Moghaddasifar; K B Lankarani; M Moosazadeh; M Afshari; A Ghaemi; M Aliramezany; R Afsar Gharebagh; M Malary
Journal:  Int J Organ Transplant Med       Date:  2016-08-01

8.  Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: Propensity score matching analysis.

Authors:  Young Joo Yang; Chang Seok Bang; Suk Pyo Shin; Gwang Ho Baik
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

9.  The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients.

Authors:  Yue-Yan Hu; Ning-Ling Dong; Qiu Qu; Xu-Fan Zhao; Hong-Ju Yang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

10.  Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.

Authors:  Yuan Li; Shousheng Liu; Yuqiang Gao; Huan Ma; Shuhui Zhan; Yan Yang; Yongning Xin; Shiying Xuan
Journal:  BMC Biochem       Date:  2019-02-06       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.